Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05601973
What this trial is testing

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Who this might be right for
Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation 60
Early research (Phase 1)Study completedNCT02789345
What this trial is testing

Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Eli Lilly and Company 29
Not applicableStudy completedNCT03761901
What this trial is testing

Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 141
Testing effectiveness (Phase 2)Looking for participantsNCT05987826
What this trial is testing

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)Study completedNCT04245085
What this trial is testing

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Who this might be right for
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
ETOP IBCSG Partners Foundation 95
Testing effectiveness (Phase 2)UnknownNCT05167851
What this trial is testing

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 68
Testing effectiveness (Phase 2)Ended earlyNCT05636267
What this trial is testing

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Who this might be right for
NSCLC
Akeso 59
Early research (Phase 1)UnknownNCT04397926
What this trial is testing

Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Sun Yat-sen University 20
Testing effectiveness (Phase 2)Study completedNCT03256136
What this trial is testing

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Who this might be right for
Lung Cancer
Massachusetts General Hospital 9
Early research (Phase 1)Study completedNCT02520778
What this trial is testing

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7+3 more
National Cancer Institute (NCI) 27
Large-scale testing (Phase 3)Not Yet RecruitingNCT07376382
What this trial is testing

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Who this might be right for
NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 680
Testing effectiveness (Phase 2)UnknownNCT05701384
What this trial is testing

Lazertinib 160mg in EGFR T790M NSCLC

Who this might be right for
Lung Cancer Stage IVEGFR T790M
Samsung Medical Center 117
Post-approval studies (Phase 4)UnknownNCT05785208
What this trial is testing

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

Who this might be right for
Non Small Cell Lung Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 122
Not applicableLooking for participantsNCT06604689
What this trial is testing

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastasases
Fudan University 800
Testing effectiveness (Phase 2)UnknownNCT03994393
What this trial is testing

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Who this might be right for
EGFR Mutant Advanced Non Small Cell Lung Cancer
University of Sydney 100
Early research (Phase 1)Study completedNCT04085315
What this trial is testing

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Who this might be right for
Lung Cancer MetastaticEGFR Gene Mutation
Collin Blakely 23
Testing effectiveness (Phase 2)Study completedNCT01866410
What this trial is testing

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer AJCC v7
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717
What this trial is testing

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute 48
Testing effectiveness (Phase 2)Study completedNCT01833572
What this trial is testing

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Who this might be right for
Non-small-cell Lung Cancer
Fudan University 36
Testing effectiveness (Phase 2)UnknownNCT05163249
What this trial is testing

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Guangdong Association of Clinical Trials 44
Next Page